{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T05:04:38Z","timestamp":1794287078533,"version":"4.9.0"},"reference-count":33,"publisher":"Informa UK Limited","issue":"6","license":[{"start":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T00:00:00Z","timestamp":1667174400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"no funding"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Human Vaccines &amp; Immunotherapeutics"],"published-print":{"date-parts":[[2022,11,30]]},"DOI":"10.1080\/21645515.2022.2126668","type":"journal-article","created":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T19:04:20Z","timestamp":1667243060000},"update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":11,"title":["Safety of mRNA BNT162b2 COVID-19 (Pfizer-BioNtech) vaccine in children aged 5\u201311 years: Results from an active pharmacovigilance study in central Italy"],"prefix":"10.1080","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9953-7769","authenticated-orcid":false,"given":"Giancarlo","family":"Ripabelli","sequence":"first","affiliation":[{"name":"Department of Medicine and Health Sciences \u201cVincenzo Tiberio\u201d, University of Molise, Campobasso, Italy"},{"name":"School of Specialization in Hygiene and Preventive Medicine, University of Molise, Campobasso, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela Lucia","family":"Sammarco","sequence":"additional","affiliation":[{"name":"Department of Medicine and Health Sciences \u201cVincenzo Tiberio\u201d, University of Molise, Campobasso, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"D\u2019Amico","sequence":"additional","affiliation":[{"name":"School of Specialization in Hygiene and Preventive Medicine, University of Molise, Campobasso, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"De Dona","sequence":"additional","affiliation":[{"name":"School of Specialization in Hygiene and Preventive Medicine, University of Molise, Campobasso, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariagrazia","family":"Iafigliola","sequence":"additional","affiliation":[{"name":"School of Specialization in Hygiene and Preventive Medicine, University of Molise, Campobasso, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albino","family":"Parente","sequence":"additional","affiliation":[{"name":"School of Specialization in Hygiene and Preventive Medicine, University of Molise, Campobasso, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicandro","family":"Samprati","sequence":"additional","affiliation":[{"name":"School of Specialization in Hygiene and Preventive Medicine, University of Molise, Campobasso, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturo","family":"Santagata","sequence":"additional","affiliation":[{"name":"School of Specialization in Hygiene and Preventive Medicine, University of Molise, Campobasso, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Adesso","sequence":"additional","affiliation":[{"name":"School of Specialization in Hygiene and Preventive Medicine, University of Molise, Campobasso, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Natale","sequence":"additional","affiliation":[{"name":"School of Specialization in Hygiene and Preventive Medicine, University of Molise, Campobasso, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela Anna","family":"Di Palma","sequence":"additional","affiliation":[{"name":"School of Specialization in Hygiene and Preventive Medicine, University of Molise, Campobasso, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Cannizzaro","sequence":"additional","affiliation":[{"name":"School of Specialization in Hygiene and Preventive Medicine, University of Molise, Campobasso, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Romano","sequence":"additional","affiliation":[{"name":"Antonio Cardarelli Hospital, Azienda Sanitaria Regionale del Molise, Campobasso, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonietta","family":"Licianci","sequence":"additional","affiliation":[{"name":"Antonio Cardarelli Hospital, Azienda Sanitaria Regionale del Molise, Campobasso, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Tamburro","sequence":"additional","affiliation":[{"name":"Department of Medicine and Health Sciences \u201cVincenzo Tiberio\u201d, University of Molise, Campobasso, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2022,10,31]]},"reference":[{"key":"e_1_3_5_2_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.663074"},{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1425"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2034765"},{"key":"e_1_3_5_5_1","unstructured":"Food and Drug Administration. FDA authorizes Pfizer-BioNtech COVID-19 vaccine for emergency use in children 5 through 11 years of age; 2021 Oct 29 [accessed 2022 Mar 16]. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-authorizes-pfizer-biontech-covid-19-vaccine-emergency-use-children-5-through-11-years-age."},{"key":"e_1_3_5_6_1","unstructured":"European Medicines Agency. Comirnaty COVID-19 vaccine: EMA recommends approval for children aged 5 to 11; 2021 Nov 25 [accessed 2022 Apr 11]. https:\/\/www.ema.europa.eu\/en\/news\/comirnaty-covid-19-vaccine-ema-recommends-approval-children-aged-5-11."},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116298"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10900-021-01039-3"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10900-022-01082-8"},{"key":"e_1_3_5_10_1","unstructured":"Agenzia Italiana del Farmaco. AIFA approva il vaccino Comirnaty per la fascia di et\u00e0 5-11 anni; 2021 Dec 1 [accessed 2022 Mar 3]. https:\/\/www.aifa.gov.it\/-\/aifa-approva-il-vaccino-comirnaty-per-la-fascia-di-et\u00e0-5-11-anni."},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00224-3"},{"key":"e_1_3_5_12_1","first-page":"352","article-title":"Vaccine storage in the community: a study in central Italy","volume":"77","author":"Grasso GM","year":"1999","unstructured":"Grasso GM, Ripabelli G, Sammarco ML, Manfredi Selvaggi TM, Quaranta A. Vaccine storage in the community: a study in central Italy. Bull World Health Organ. 1999;77:352\u201355.","journal-title":"Bull World Health Organ"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034577"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/pai.13401"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13052-021-01074-9"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-021-04330-6"},{"key":"e_1_3_5_17_1","unstructured":"Centers for Disease Control and Prevention (CDC). Potential rapid increase of omicron variant infections in the United States; 2021 Dec 20 [accessed 2022 Mar 26]. https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/science\/forecasting\/mathematical-modeling-outbreak.html."},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00948"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmaid.2014.01.008"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm705152a1"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2022.01.032"},{"key":"e_1_3_5_22_1","unstructured":"European Medicines Agency. Comirnaty: ePAR - product information; 2022 May 6 [accessed 2022 May 12]. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/comirnaty."},{"key":"e_1_3_5_23_1","unstructured":"Italian Medicines Agency. Report on pharmacovigilance on COVID-19 vaccines n. 11 27\/12\/2020-26\/03\/2022; [accessed 2022 May 15]. https:\/\/www.aifa.gov.it\/web\/guest\/farmacovigilanza-vaccini-covid-19."},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10020233"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.29516"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcle.2021.06.018"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.3390\/medicina58020197"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107456"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.acra.2021.04.007"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1136\/pmj.78.920.327"},{"key":"e_1_3_5_31_1","unstructured":"European Medicines Agency. EMA recommends approval of Spikevax for children aged 6 to 11; 2022 Feb 24 [accessed 2022 May 11]. https:\/\/www.ema.europa.eu\/en\/news\/ema-recommends-approval-spikevax-children-aged-6-11."},{"key":"e_1_3_5_32_1","unstructured":"Australian Technical Advisory Group on Immunisation. ATAGI recommendations on the use of Spikevax (Moderna) COVID-19 vaccine in children aged 6 to 11 years. Australian Government Department of Health; 2022 Feb 23 [accessed 2022 May 11]. https:\/\/www.health.gov.au\/news\/atagi-recommendations-on-the-use-of-spikevax-moderna-covid-19-vaccine-in-children-aged-6-to-11-years."},{"key":"e_1_3_5_33_1","unstructured":"Health Canada. Health Canada authorizes use of the Moderna Spikevax (50 mcg) COVID-19 vaccine in children 6 to 11 years of age; 2022 Mar 17 [accessed 2022 May 11]. https:\/\/www.canada.ca\/en\/health-canada\/news\/2022\/03\/health-canada-authorizes-use-of-the-moderna-spikevax-50-mcg-covid-19-vaccine-in-children-6-to-11-years-of-age.html."},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203315"}],"container-title":["Human Vaccines &amp; Immunotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/21645515.2022.2126668","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T17:47:42Z","timestamp":1737049662000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/21645515.2022.2126668"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,31]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,11,30]]}},"alternative-id":["10.1080\/21645515.2022.2126668"],"URL":"https:\/\/doi.org\/10.1080\/21645515.2022.2126668","relation":{},"ISSN":["2164-5515","2164-554X"],"issn-type":[{"value":"2164-5515","type":"print"},{"value":"2164-554X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,31]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=khvi20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=khvi20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-07-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-12","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"2126668"}}